Saruparib combinations · EvoPAR-BR01
The registry tests saruparib plus camizestrant or endocrine therapy against specified comparators. This cannot be summarized as standalone camizestrant success or conflated with SERENA-6. camizestrant — phase 3 study in Advanced Breast Cancer. NCT06380751 lists Progression-Free Survival (Arm 1 vs arm 2) as a primary outcome (Up to approximately 64 months). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2029-12-18 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Phase 3 combination monitor — date unconfirmed
Potential outcome market
Will the prespecified saruparib-plus-camizestrant comparison in EvoPAR-BR01 meet its defined PFS criterion by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.